Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Cempra’s Antibiotic Drug Close To Receiving FDA Approval

XTALKS VITALS NEWS

FDA

Despite the committee’s decision, analysts are not convinced that the FDA will follow their recommendation to approve solithromycin.

Share this!

November 8, 2016 | by Sarah Hand, M.Sc.

An independent advisory panel to the US Food and Drug Administration (FDA), has voted 7-6 that the regulatory agency should approve Cempra’s antibiotic drug, solithromycin. The close vote found that solithromycin’s ability to combat community-acquired bacterial pneumonia (CABP) outweighed its potential risks.

While the drug showed efficacy across multiple clinical trials, the committee was concerned about the drug’s potentially negative effects on the liver. The FDA advisory committee concluded that Cempra had failed to provide sufficient safety data on solithromycin, in order to fully assess its risks.

“We appreciate the meaningful discussion from today’s panel,” said Dr. Prabhavathi Fernandes, president and CEO of Cempra. “Their supportive view and thoughtful comments on approaches to ensuring appropriate use are consistent with Cempra’s commitment to make solithromycin available to the right patients for a five to seven day course of an oral and/or IV macrolide as monotherapy for CABP.”



Despite the committee’s decision, analysts are not convinced that the FDA will follow their recommendation to approve solithromycin. Though the FDA often does follow the guidance of the independent advisory panel, it is not obligated to do so.

“Antibiotic resistance is reaching alarming rates across the globe,” said Fernandes. “In the U.S. alone, pneumonia is the leading cause of death due to infectious disease and rates of pneumococcal resistance to current macrolides for the treatment of CABP can exceed 50 percent. We believe solithromycin has the potential to offer patients and physicians an important new treatment option and we look forward to continuing to work with the FDA as it completes its review.”

If solithromycin gains regulatory approval, it will be the first new macrolide antibiotic with both an oral and an IV formulation in more than 20 years. Cempra is also awaiting an approval decision by the European Medicines Agency (EMA).


Keywords: Antibiotic, FDA, Clinical Trials


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.